Akebia Therapeutics公司近日宣布,其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性,标志着公司在肾脏疾病治疗领域的重要进展。
篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果,有望加速罕见病治疗方案的开发进程。此次试验的推进,将为进一步验证AKB-097的临床潜力提供关键数据支持。
Akebia Therapeutics公司近日宣布,其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性,标志着公司在肾脏疾病治疗领域的重要进展。
篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果,有望加速罕见病治疗方案的开发进程。此次试验的推进,将为进一步验证AKB-097的临床潜力提供关键数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.